Search company, investor...

About Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Headquarters Location

475 Huntington Drive

San Marino, California, 91108,

United States

626-441-6695

Loading...

Loading...

Epeius Biotechnologies Patents

Epeius Biotechnologies has filed 6 patents.

The 3 most popular patent topics include:

  • biotechnology
  • genetics
  • molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/8/2018

4/7/2020

Molecular biology, Biotechnology, Posttranslational modification, Genetics, Transcription factors

Grant

Application Date

2/8/2018

Grant Date

4/7/2020

Title

Related Topics

Molecular biology, Biotechnology, Posttranslational modification, Genetics, Transcription factors

Status

Grant

Epeius Biotechnologies Frequently Asked Questions (FAQ)

  • Where is Epeius Biotechnologies's headquarters?

    Epeius Biotechnologies's headquarters is located at 475 Huntington Drive, San Marino.

  • Who are Epeius Biotechnologies's competitors?

    Competitors of Epeius Biotechnologies include Minerva Biotechnologies, Dicerna Pharmaceuticals, Elusys Therapeutics, Clarus Therapeutics, MaxCyte and 7 more.

Loading...

Compare Epeius Biotechnologies to Competitors

E
Emiliem

Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

B
Biosceptre International

Biosceptre International is a company focused on the development of innovative cancer therapies, operating within the biotechnology and healthcare sectors. The company's main offerings include the development of a multi-targeted universal CAR T system, which is designed to improve the lives of cancer patients by potentially treating a wide range of malignancies. Biosceptre primarily serves the healthcare industry, specifically the cancer treatment sector. It is based in Cambridge, England.

T
Targeson

Targeson is a biotechnology company that develops, manufactures, and markets ultrasound contrast agent technologies for pre-clinical molecular imaging in animal models. Targeson is also developing this technology for site-specific diagnosis and therapy in humans. The company has engineered a versatile microparticle platform that may be used as both a contrast agent and, in a slightly modified form, a drug or gene delivery agent. Targeson manufactures and sells the Targestarline of contrast agents for ultrasound-based molecular and functional imaging in animal models of disease. Targeson's agents can be readily targeted to the molecular signature of many diseases, and can be used to detect pathophysiology on the molecular level. The company's intellectual property aims to enable the agents to bind with high efficiency to the intended molecular targets. In addition, the company is investigating therapeutic technology for simultaneous imaging and delivery, which aims to enable the user to verify that the therapeutic compound has been delivered to the intended site.

A
Aliva Biopharmaceuticals

Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.

B
BioForce Nanosciences

BioForce Nanosciences is a company that focuses on the development and commercialization of nanotech instruments, consumables, and applications within the life sciences sector. The company's main offerings include molecular printers that precisely deliver liquids to surfaces, UV/Ozone cleaners, and surface patterning tools, all of which are designed to assist in the development of ultraminiaturized devices and methods. BioForce Nanosciences primarily serves the life sciences industry. It was founded in 1994 and is based in Ames, Iowa.

C
Cell Point

Cell Point is a biotechnology company, develops radiodiagnostic imaging and intracellular therapeutic agents, and delivery systems for the administration of local regional radio/chemotherapy.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.